A
Aardvark Therapeutics
The development and commercialization of safe and effective small molecule therapeutics that have broad therapeutic potential
About Aardvark Therapeutics
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of safe and effective small molecule therapeutics. The company's lead product, ARD 101, is an oral drug designed to have low systemic exposure while activating gut peptide hormone secretion and gut-brain signaling. This innovative approach aims to treat a variety of metabolic and inflammatory diseases. Aardvark Therapeutics operates in the biopharmaceutical market, primarily serving patients with complex medical conditions that require advanced therapeutic solutions. The company generates revenue through the development and eventual commercialization of its drug candidates, with a focus on achieving regulatory approval and market entry. Chief Medical Officer Dr. Andreas Niethammer, who has extensive experience in translational medicine and executive roles at major pharmaceutical companies, leads the clinical development efforts. Key aspects of Aardvark's business model include leveraging preclinical and clinical data to support the efficacy and safety of its drug candidates, and focusing on the therapeutic potential of bitter taste receptors (Tas2Rs), which are expressed on many cells throughout the body. The company aims to address unmet medical needs by providing novel treatments that offer broad therapeutic potential.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2025 | $94M | $94M | Undisclosed | ↗ |
| SERIES COther financing | May 2024 | $85M | $340M | Vickers Venture Partners · Cantor Fitzgerald · LG Technology Ventures · Foundation for Prader-Willi Syndrome Research | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Aardvark Therapeutics is 6.3K monthly website visits, up 34% over the last three months. Aardvark Therapeutics's team grew 126.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aardvark Therapeutics in the San Diego ecosystem
The Aardvark Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Vickers Venture Partners- BIBNH Investment
Premier Partners
Korea Omega Investment
Sorrento Therapeutics
Foundation for Prader-Willi Syndrome Research
Series B and later11 investors entered at this stage
Decheng Capital
Cantor Fitzgerald
LG Technology Ventures
Walleye Capital
Surveyor Capital
SymBiosis
Prader-Willi Syndrome Association USA
Cormorant Asset Management
Tetragon Financial Group
Laurion Capital Management
Silver Arch Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aardvark Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aardvark Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










